Investor and Media Relations
Chief Communications Officer
Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc.
300 Park Avenue
New York, NY 10022
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.
On January 24, 2019, Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced the completion of its previously disclosed merger with Apricus Biosciences, Inc. Seelos Therapeutics, Inc. began trading on January 24, 2019 on The Nasdaq Capital Market under the ticker symbol “SEEL”. Seelos maintains its headquarters in New York, New York and is led by Chairman, Founder, and Chief Executive Officer, Raj Mehra, Ph.D.
Seelos rang the Nasdaq Stock Market opening bell on August 12, 2019 at 9:30 am E.T., at the Nasdaq MarketSite in Times Square.
This website and the conference calls, press releases, presentations and other materials posted on, or available through, this website, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements that are not purely historical are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Seelos that any of its plans will be achieved. Such forward-looking statements include, among other things: Seelos’s ability to identify and conclude strategic transactions or other business combinations; the timing of any clinical and non-clinical trials and studies; Seelos’s development and partnering plans; Seelos’s ability to fund its operations with cash on hand through 2019; and Seelos’s strategic objectives. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Seelos, including, but not limited to: Seelos’s financial position and need for additional capital to fund its operations, which may be adversely impacted if Seelos is unable to maintain the continued listing of its common stock; a partnership with respect to any larger strategic transaction or other business combination may not be available on acceptable terms or at all; Seelos’s ability to retain and attract key personnel; Seelos’s ability to raise additional funding that it may need to continue to pursue its development plans; Seelos’s ability to secure a strategic partner; Seelos may expend cash resources more quickly than it anticipates; and market conditions. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as prediction of future events. All forward-looking statements are qualified in their entirety by this cautionary statement, and Seelos assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the applicable conference calls, press releases, presentations and other materials. Readers are urged to read the risk factors set forth in Seelos’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the Securities and Exchange Commission (the “SEC”). Copies of these reports are available free of charge on our website at https://seelostherapeutics.com/ or from the SEC’s website at https://www.sec.gov.